Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here is What Hedge Funds Think About Sagent Pharmaceuticals Inc (SGNT): Momenta Pharmaceuticals, Inc. (MNTA), Hi-Tech Pharmacal Co. (HITK)

Sagent Pharmaceuticals IncIs Sagent Pharmaceuticals Inc (NASDAQ:SGNT) an exceptional investment right now? Money managers are becoming hopeful. The number of long hedge fund bets improved by 3 in recent months.

In today’s marketplace, there are tons of indicators shareholders can use to track the equity markets. A pair of the most innovative are hedge fund and insider trading interest. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the top investment managers can outperform the market by a healthy margin (see just how much).

Just as key, optimistic insider trading activity is another way to parse down the investments you’re interested in. As the old adage goes: there are a variety of incentives for a bullish insider to sell shares of his or her company, but just one, very clear reason why they would initiate a purchase. Various empirical studies have demonstrated the market-beating potential of this method if “monkeys” know what to do (learn more here).

Keeping this in mind, let’s take a gander at the latest action encompassing Sagent Pharmaceuticals Inc (NASDAQ:SGNT).

How have hedgies been trading Sagent Pharmaceuticals Inc (NASDAQ:SGNT)?

At year’s end, a total of 11 of the hedge funds we track were long in this stock, a change of 38% from the third quarter. With the smart money’s sentiment swirling, there exists a select group of notable hedge fund managers who were increasing their stakes substantially.

When looking at the hedgies we track, James E. Flynn’s Deerfield Management had the most valuable position in Sagent Pharmaceuticals Inc (NASDAQ:SGNT), worth close to $34.6 million, accounting for 1.9% of its total 13F portfolio. The second largest stake is held by Jerome Pfund and Michael Sjostrom of Sectoral Asset Management, with a $12.8 million position; 0.4% of its 13F portfolio is allocated to the stock. Remaining hedge funds that are bullish include Jacob Gottlieb’s Visium Asset Management, Mark Kingdon’s Kingdon Capital and Dmitry Balyasny’s Balyasny Asset Management.

Now, key hedge funds have jumped into Sagent Pharmaceuticals Inc (NASDAQ:SGNT) headfirst. Kingdon Capital, managed by Mark Kingdon, initiated the largest position in Sagent Pharmaceuticals Inc (NASDAQ:SGNT). Kingdon Capital had 5.1 million invested in the company at the end of the quarter. D. E. Shaw’s D E Shaw also initiated a $0.4 million position during the quarter. The only other fund with a brand new SGNT position is David Cohen and Harold Levy’s Iridian Asset Management.

How have insiders been trading Sagent Pharmaceuticals Inc (NASDAQ:SGNT)?

Insider purchases made by high-level executives is best served when the company in focus has experienced transactions within the past six months. Over the last half-year time period, Sagent Pharmaceuticals Inc (NASDAQ:SGNT) has seen zero unique insiders purchasing, and 1 insider sales (see the details of insider trades here).

Let’s check out hedge fund and insider activity in other stocks similar to Sagent Pharmaceuticals Inc (NASDAQ:SGNT). These stocks are Akorn, Inc. (NASDAQ:AKRX), Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR), Hi-Tech Pharmacal Co. (NASDAQ:HITK), and Ligand Pharmaceuticals Inc. (NASDAQ:LGND). All of these stocks are in the drugs – generic industry and their market caps are similar to SGNT’s market cap.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.